home All News open_in_new Full Article

Biontech macht im ersten Quartal Millionenverlust, plant aber Zulassung von Krebsmedikament

Viel Geld für Forschungsarbeit hat dem Pharmaunternehmen Biontech im ersten Quartal einen hohen Verlust eingebracht. Die Firma möchte bei der Zulassung von Krebsmedikamenten Tempo machen.


today 17 h. ago attach_file Society

attach_file Society
attach_file Economics
attach_file Society
attach_file Society
attach_file Society
attach_file Society
attach_file Society
attach_file Society
attach_file Economics
attach_file Economics
attach_file Society
attach_file Society
attach_file Society
attach_file Society
attach_file Society
attach_file Economics
attach_file Society
attach_file Society
attach_file Society
attach_file Economics


ID: 1972736984
Add Watch Country

arrow_drop_down